Nymox gets CE Mark for saliva-based tobacco test

By Elaine Rigoli

Tampa, Fla., May 5 - Nymox Pharmaceutical Corp. said Friday the saliva-based version of its NicAlert product for testing for tobacco use or exposure has now achieved certification in Europe with the CE Mark, making the product eligible for sale in the European Union.

NicAlert Saliva uses Nymox's patented technology to provide an easy-to-use, on-site visual read-out of an individual's level of tobacco use or exposure, the company said in a news release.

The urine-based version of NicAlert earlier received clearance from the Food and Drug Administration and achieved certification with the CE Mark, the release said.

Nymox is a pharmaceutical company based in Hasbrouck Heights, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.